Introduction
Professor Hu Xichun (胡夕春) is the Chief of Medical Oncology at Fudan University Shanghai Cancer Center (FUSCC) — one of China's most prestigious and highest-volume cancer centers. Professor Hu is widely recognized as one of China's foremost medical oncologists, with particular expertise in breast cancer chemotherapy, targeted therapy, and immunotherapy. As the leader of FUSCC's Medical Oncology Department, he oversees one of China's most comprehensive breast cancer medical oncology programs. His expertise spans the full spectrum of breast cancer systemic treatment, with particular distinction in HER2-positive breast cancer, triple-negative breast cancer, hormone receptor-positive breast cancer, and metastatic breast cancer management. International patients with breast cancer consistently regard Professor Hu as one of China's premier choices for expert medical oncology care.
Academic Distinctions & Leadership
- Chief of Medical Oncology, Fudan University Shanghai Cancer Center (FUSCC)
- Professor of Oncology, Fudan University Shanghai Medical College
- Director, Medical Oncology Department, FUSCC
- Member, Chinese Society of Clinical Oncology (CSCO)
- Breast Cancer Committee Member, CSCO
- Member, Chinese Anti-Cancer Association, Breast Cancer Committee
- Editorial Board Member, multiple Chinese and international oncology journals
- Recipient, multiple national and Shanghai municipal science and technology awards
- Visiting professor at leading cancer centers internationally
Specializations & Expertise
HER2-Positive Breast Cancer
- Trastuzumab-based chemotherapy regimens
- Pertuzumab + trastuzumab dual HER2 blockade
- T-DM1 (ado-trastuzumab emtansine) for metastatic HER2+ breast cancer
- T-DXd (trastuzumab deruxtecan) for HER2+ and HER2-low breast cancer
- Neratinib for extended adjuvant therapy
- Lapatinib-based regimens for brain metastases
- Tucatinib combinations for HER2+ metastatic breast cancer
Triple-Negative Breast Cancer (TNBC)
- Neoadjuvant chemotherapy for TNBC
- Immunotherapy (pembrolizumab) + chemotherapy for TNBC
- PARP inhibitors for BRCA-mutated TNBC
- Sacituzumab govitecan for metastatic TNBC
- Capecitabine adjuvant therapy for residual TNBC
Hormone Receptor-Positive Breast Cancer
- CDK4/6 inhibitor combinations (palbociclib, ribociclib, abemaciclib)
- Endocrine therapy optimization (aromatase inhibitors, fulvestrant)
- PI3K/AKT/mTOR pathway inhibitors (alpelisib, everolimus)
- ESR1 mutation management
- Ovarian suppression for premenopausal patients
Metastatic Breast Cancer
- Comprehensive metastatic breast cancer management
- Brain metastases treatment
- Bone metastases management
- Visceral crisis management
- Clinical trial access for novel agents
Clinical Excellence & Innovation
- Breast Cancer Authority: One of China's foremost experts in breast cancer medical oncology, with extensive experience in all breast cancer subtypes and treatment modalities
- Novel Agent Access: Active participation in clinical trials of novel breast cancer agents, providing patients access to cutting-edge treatments
- HER2-Low Breast Cancer: Expert in the emerging field of HER2-low breast cancer treatment with T-DXd
- Multidisciplinary Integration: Seamless collaboration with FUSCC's breast surgery, radiation oncology, and pathology teams for comprehensive breast cancer care
- National Guidelines: Active contributor to China's national breast cancer treatment guidelines
Research & Academic Contributions
Professor Hu is one of China's most prolific breast cancer researchers with numerous peer-reviewed publications in leading Chinese and international oncology journals including JCO, Lancet Oncology, and Annals of Oncology. His research focuses on breast cancer systemic treatment, novel targeted agents, and immunotherapy.
Hospital Affiliation
Fudan University Shanghai Cancer Center (FUSCC)
270 Dongan Road, Xuhui District, Shanghai 200032
FUSCC is one of China's most prestigious and comprehensive cancer centers, featuring:
- One of China's highest-volume breast cancer programs
- Comprehensive breast cancer MDT
- Access to novel agents through clinical trials
- Advanced molecular profiling (NGS, HER2, PD-L1)
- Radiation oncology, breast surgery, and pathology integration
- International patient services with English-speaking coordinators
Why Choose Professor Hu Xichun?
- Breast Cancer Authority: Chief of one of China's most respected breast cancer medical oncology programs
- Novel Agent Access: Clinical trial access to the latest breast cancer treatments
- All Subtypes Expertise: HER2+, TNBC, HR+, and HER2-low breast cancer
- Comprehensive Cancer Center: FUSCC's world-class multidisciplinary oncology environment
- Cost-Effective Excellence: Breast cancer treatment costs in Shanghai are typically 60-80% lower than in the US or Europe
- Proven International Track Record: Trusted by patients from around the world
Conditions Treated
- HER2-positive breast cancer (early and metastatic)
- Triple-negative breast cancer (early and metastatic)
- Hormone receptor-positive breast cancer (early and metastatic)
- HER2-low breast cancer
- Inflammatory breast cancer
- Male breast cancer
- Breast cancer with brain metastases
International Patient Services
China Medical Concierge - Shanghai (CMCS) provides comprehensive support for international patients seeking breast cancer medical oncology care with Professor Hu Xichun at FUSCC.
Pre-Arrival Support
- Medical Record Review: Review of your pathology, receptor status (ER/PR/HER2), staging CT/PET, and prior treatment history
- Virtual Consultation: Video consultation with Professor Hu's team
- MDT Review: Arrangement of multidisciplinary breast cancer team review
- Treatment Planning: Personalized systemic treatment plan
- Cost Transparency: Detailed cost estimate including consultations and treatment
- Visa Assistance: Medical visa guidance and invitation letters
- Travel Arrangements: Flights, airport pickup, and accommodation near the hospital
During Treatment
- Professional Medical Interpretation: Experienced oncology interpreters at all appointments
- Hospital Navigation Support: Registration, payment, and hospital navigation assistance
- Chemotherapy Support: Accompaniment and support during chemotherapy infusions
- 24/7 Support: Round-the-clock assistance for any concerns
Post-Treatment Care
- Report Translation: Complete translation of all pathology and treatment reports
- Treatment Summary: Comprehensive oncology summary for your home oncologist
- Medication Guide: Detailed oral medication and targeted therapy instructions
- Telemedicine Follow-up: Virtual follow-up with Professor Hu's team
- Long-term Support: Ongoing assistance after returning home
Schedule Your Consultation
If you or a loved one has breast cancer and is seeking expert medical oncology care, Professor Hu Xichun at Fudan University Shanghai Cancer Center offers world-class breast cancer expertise at a fraction of Western costs.
Contact China Medical Concierge - Shanghai today to request a pathology and staging review, schedule a virtual consultation, and begin planning your journey to Shanghai for expert breast cancer care.
Bridging international patients with Shanghai's finest breast cancer oncologists — because your breast cancer care deserves the expertise of China's most experienced medical oncology team.
0 comments